Current use of intralesional cidofovir for recurrent respiratory papillomatosis

Authors

  • Craig S. Derkay MD,

    Corresponding author
    1. Department of Otolaryngology–Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, Virginia, U.S.A.
    • Vice-Chairman, Department of Otolaryngology, Director, Pediatric Otolaryngology, Eastern Virginia Medical School, Children's Hospital of the King's Daughters, 601 Children's Lane, 2nd Floor, Norfolk, VA 23507
    Search for more papers by this author
  • Peter G. Volsky MD,

    1. Department of Otolaryngology–Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, Virginia, U.S.A.
    Search for more papers by this author
  • Clark A. Rosen MD,

    1. Department of Otolaryngology–Head and Neck Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, U.S.A
    Search for more papers by this author
  • Seth M. Pransky MD,

    1. Department of Surgery, Division of Otolaryngology–Head and Neck Surgery, Children's Hospital of San Diego, San Diego, California, U.S.A
    Search for more papers by this author
  • J. Scott McMurray MD,

    1. Department of Surgery, Division of Otolaryngology–Head and Neck Surgery, University of Wisconsin, Madison, Wisconsin, U.S.A
    Search for more papers by this author
  • Neil K. Chadha MBChB(Hons), MPHe BSc(Hons),

    1. British Columbia Children's Hospital, Vancouver, British Columbia, Canada
    Search for more papers by this author
  • Patrick Froehlich MD

    1. Department of Pediatric Otolaryngology, Montreal Children's Hospital, Montreal, Quebec, Canada
    Search for more papers by this author

  • All work was performed at Eastern Virginia Medical School, revisions made via e-mail correspondence and teleconference, with consensus statement review and approval at the Recurrent Respiratory Papillomatosis Task Force meeting on April 19, 2012 at the 115th Annual Meeting of the Triological Society in San Diego, California, U.S.A.

  • The authors have no funding, financial relationships, or conflicts of interest to disclose.

Abstract

Objectives/Hypothesis:

The authors sought to define the indications, administration, and adverse events associated with intralesional cidofovir use for recurrent respiratory papillomatosis (RRP).

Study Design:

Cross-sectional study.

Methods:

A 21-question online survey was distributed to 115 selected adult and pediatric laryngeal surgeons internationally. Results were used to draft statements of best practice, which were approved by the full membership of the RRP Task Force.

Results:

Eighty-two surgeons, who altogether presently manage 3,043 patients with RRP, responded to the survey. Seventy-four surgeons previously used cidofovir, reporting 1,248 patients in the last decade (estimated 801 adults and 447 children). Single indications for adjuvant cidofovir included six or more surgeries per year, increasing frequency of surgery, and extralaryngeal spread (in children). Most adult surgeons use 20 to 40 mg in <4 mL; pediatric surgeons use <20 mg in <2 mL. Scheduled administration following an initiation trial of five injections is common; cidofovir is discontinued following a complete response. Most surgeons biopsy routinely, use special informed consent, and are willing to participate in multi-institutional clinical trials on cidofovir uses, efficacy, and safety.

Conclusions:

Eighteen statements were approved by the RRP Task Force after discussion of the survey results. Intralesional cidofovir may be initiated if surgical debulking is required every 2 to 3 months. The concept of an adjuvant regimen with regular biopsy is favored. Administration should remain below established safe limits of dosing (3 mg/kg) and volume. Informed consent, including discussion of off-label use and acute kidney injury in children, is important. A special consent form sample is included. There remains a need for high-quality data. Laryngoscope, 2013

Ancillary